Lipoxin analogs: Novel anti-inflammatory mediators

Current Opinion in Investigational Drugs

Volumn 6, Issue 11, 2005, Pages 1112-1115

  Gewirtz, Andrew T ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Anti inflammatory; Inflammatory bowel disease; Lipoxin A4; Lipoxin analogs

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; LIPOXIN; LIPOXIN A; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TOLERABILITY; ENTERITIS; ENZYME INHIBITION; EX VIVO STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; NONHUMAN; PSORIASIS; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; LIPOXINS; SIGNAL TRANSDUCTION;

EID: 28244491490     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Serhan CN, Hamberg M, Samuelsson B: Lipoxins: Novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci USA (1984) 81(17):5335-5339.
2. 4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo. J Med Chem (2004) 47(8):2157-2165.
3. 4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry (1995) 34(44):14609-14615.
4. Claria J, Serhan CN: Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA (1995) 92(21):9475-9479.
5. Fiorucci S, Distrutti E, Mencarelli A, Morelli A, Laufor SA, Cirino G, Wallace JL: Evidence that 5-lipoxygenase and acetylated cyclooxygenase-2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin. Br J Pharmacol (2003) 139(7):1351-1359.
6. Fiorucci S, Distrutti E, de Lima OM, Romano M, Mencarelli A, Barbanti M, Palazzini E, Morelli A, Wallace JL: Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J (2003) 17(9):1171-1173.
7. 4, and their analogs selectively downregulate PMN azurophilic degranulation. Am J Physiol (1999) 276(4 Pt 1):C988-C994.
8. 4. FASEB J (1999) 13(8):903-911.
9. 4 analogs. J Clin Invest (1998) 101(9):1860-1869.
10. 4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J Clin Invest (1993) 92(1):75-82.
11. 4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol (2002) 168(10):5260-5267.
12. Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR: Cutting edge: Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol (2000) 164(4):1663-1667.
13. Aliberti J, Hieny S, Reis e Sousa C, Serhan CN, Sher A: Lipoxin-mediated inhibition of IL-12 production by DCs: A mechanism for regulation of microbial immunity. Nat Immunol (2002) 3(1):76-82.
14. 4 receptor. J Exp Med (1994) 180(1):253-260.
15. 4's anti-inflammatory actions on intestinal epithelium. Am J Physiol Cell Physiol (2003) 284(4):C888-C896.
16. 4 stable analogues. J Clin Invest (1998) 101(4):819-826.
17. 4 and regulation of vascular and inflammatory responses. Am J Pathol (2001) 158(1):3-9.
18. Bannenberg G, Moussignac RL, Gronert K, Devchand PR, Schmidt BA, Guilford WJ, Bauman JG, Subramanyam B, Perez HD, Parkinson JF, Serhan CN: Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br J Pharmacol (2004) 143(1):43-52.
19. 4 stable analog displays a unique topical anti-inflammatory profile. J Immunol (2002) 169(12):7063-7070.
20. McMahon B, Godson C: Lipoxins: Endogenous regulators of inflammation. Am J Physiol Renal Physiol (2004) 286(2):F189-F201.
21. 4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci USA (2004) 101(44):15736-15741.
22. Karp CL, Flick LM, Park KW, Softic S, Greer TM, Keledjian R, Yang R, Uddin J, Guggino WB, Atabani SF, Belkaid Y et al: Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol (2004) 5(4):388-392.
23. 4 stable analogues are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors. J Exp Med (1997) 185(9):1693-1704.
24. 4 on airway responses in asthmatic subjects. Am Rev Respir Dis (1992) 145(6):1281-1284.
25. Bonnans C, Chanez P, Chavis C: Lipoxins in asthma: Potential therapeutic mediators on bronchial inflammation? Allergy (2004) 59(10):1027-1041.
26. Mangino M, Brounts L, Harms B: Colonic lipoxin synthesis in patients with inflammatory bowel disease (IBD). FASEB J (2005) 19:Abs 1526.